Addressing large, unmet global markets with innovative proprietary products More »
Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »
Identifying early-stage companies with potential to increase value for shareholders More »
OPKO continues to make progress with its program to build a company capable of long-term growth and increasing value to its investors and I would like to review several highlights.
OPKO Completes Acquisition of Bio-Reference Laboratories.
OPKO Investee Zebra Biologics Announces Collaboration with AbbVie to Discover New Antibody Therapeutics more »
OPKO Announces Initiation of Claros(R) 1 Clinical Trial for Total PSA more »
OPKO Health to Present at the J.P. Morgan 35th Annual Healthcare Conference more »
OPKO Health is an opportunistic research and development company that targets large, high-growth markets.
FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease click here »